Related Experiment Video
Updated: Jan 3, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway
Maria L Jaramillo1, Myriam Banville, Catherine Collins
1Biotechnology Research Institute, National Research Council of Canada, Montreal, Quebec, Canada. maria.jaramillo@nrc.ca
Abstract:
It has been demonstrated that A549 non-small cell lung cancer (NSCLC) cells are sensitive to epidermal growth factor receptor (EGFR) inhibitors in in vivo xenograft animal models, but are relatively resistant in conventional in vitro monolayer growth assays. Here, we utilized anchorage-independent cell growth/survival assays as well as motility assays and demonstrated that these tests detect the effects of two EGFR inhibitors, the small molecule inhibitor AG1478 and the ligand-blocking antibody 225 mAb, on A549 cells more sensitively than monolayer growth assays. AG1478 was more effective than 225 mAb at inhibiting EGF-stimulated anchorage-independent cell growth, in part due to its pronounced ability to inhibit cell survival, whereas 225 mAb and AG1478 were both able to inhibit cell motility. In order to determine which EGFR signalling pathway components were most strongly associated with these cell responses, we analyzed in parallel the phosphorylation levels of EGFR itself as well as several downstream pathway elements. We found that the limited ability of 225 mAb to inhibit MAPK, PI3K and STAT3 phosphorylation correlated with its inability to promote anchorage independent apoptosis, but did not correlate with its ability to inhibit motility. Based on our results in A549 cells, we propose that EGF stimulates tumour progression of NSCLC largely through effects on anchorage-independent growth and survival, as well as motility.
Insights
Epidermal growth factor receptor (EGFR) inhibitors show differential effects on non-small cell lung cancer (NSCLC) cells. Anchorage-independent assays are more sensitive for detecting EGFR inhibitor efficacy in NSCLC progression.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- A549 non-small cell lung cancer (NSCLC) cells exhibit resistance to epidermal growth factor receptor (EGFR) inhibitors in standard in vitro assays.
- In vivo models show sensitivity of NSCLC cells to EGFR inhibitors, highlighting a discrepancy in assessment methods.
Purpose of the Study:
- To evaluate the sensitivity of anchorage-independent cell growth and motility assays in detecting EGFR inhibitor effects on A549 NSCLC cells.
- To compare the efficacy of a small molecule EGFR inhibitor (AG1478) and a ligand-blocking antibody (225 mAb) on NSCLC cell behavior.
- To correlate EGFR signaling pathway activation with cellular responses to EGFR inhibition.
Main Methods:
- Utilized anchorage-independent cell growth/survival and motility assays to assess EGFR inhibitor effects.
- Compared the efficacy of AG1478 and 225 mAb in inhibiting EGF-stimulated A549 cell growth and motility.
- Analyzed phosphorylation levels of EGFR and downstream signaling molecules (MAPK, PI3K, STAT3) in response to EGFR inhibitors.
Main Results:
- Anchorage-independent assays and motility assays were more sensitive than monolayer assays for detecting EGFR inhibitor effects.
- AG1478 demonstrated greater inhibition of EGF-stimulated anchorage-independent growth and survival compared to 225 mAb.
- Both AG1478 and 225 mAb inhibited cell motility, but 225 mAb's limited effect on MAPK, PI3K, and STAT3 phosphorylation correlated with its reduced ability to induce apoptosis.
Conclusions:
- EGF promotes NSCLC tumor progression through anchorage-independent growth, survival, and motility.
- Anchorage-independent assays provide a more sensitive platform for evaluating EGFR inhibitor efficacy in NSCLC.
- Differential effects of EGFR inhibitors on signaling pathways explain their varied impact on NSCLC cell behavior.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
